clinical trial · NCT05633160
64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)
Prostatic NeoplasmsCastration-Resistant64Cu-SAR-BBN67Cu-SAR-BBN
brief summary
The aim for this study is to determine the safety and efficacy of 67Cu-SAR-BBN in participants with Gastrin Releasing Peptide Receptor (GRPR)-expressing metastatic castrate resistant prostate cancer in patients who are ineligible for therapy with 177Lu-PSMA-617.
started
Jun 15, 2023
primary completion
Apr 23, 2025
completion
Apr 23, 2025
last updated
Aug 29, 2025
official title
A Phase I/IIa Theranostic Study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for Identification and Treatment of GRPR-expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol